3/26
08:00 am
mgtx
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
High
Report
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
3/11
07:18 am
mgtx
MeiraGTx (MGTX) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
MeiraGTx (MGTX) was upgraded by Zacks Research from "strong sell" to "hold".
2/3
08:00 am
mgtx
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
Low
Report
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
2/3
07:12 am
mgtx
MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/28
01:07 pm
mgtx
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]
Low
Report
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]
1/2
08:44 am
mgtx
MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors [Seeking Alpha]
Medium
Report
MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors [Seeking Alpha]